FDA Grants Kamada Orphan Drug Designation for the Treatment of Graft versus Host Disease

Kamada Ltd. , a plasma-derived protein therapeutics company focused on orphan indications, announces that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for GlassiaA , the Company's proprietary human Alpha-1 Antitrypsin , to treat Graft-versus-host-disease . Orphan drug designation carries multiple benefits, including the availability of grant money, certain tax credits and seven years of market exclusivity, as well as the possibility of an expedited regulatory process.

http://ift.tt/1p0PDf8